NDA 022267 · Abbvie INC
Depakote Er
Divalproex Sodium · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Oct 15, 2009 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Mar 24, 2008
Approved uses
2
Original approval plus efficacy supplements
Registered trials
398
85 Phase 3, 16 recruiting
FAERS reports
46,653
31,288 serious, 2,596 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 15, 2009 Supplement 1 · Efficacy LabelLetter
- Mar 24, 2008 Original approval · Type 6 - New Indication (no longer used) · priority review LabelReviewOther Important Information from FDA
2 products under this application
- DEPAKOTE ER · DIVALPROEX SODIUM 500MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- DEPAKOTE ER · DIVALPROEX SODIUM 250MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Divalproex" as an intervention, any sponsor and status, largest first.
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed EpilepsyPivotal-lookingCompleted
UCB PharmaUCB
NCT00175903 · 1,701 participants · Start Feb 2005 · Primary completion Oct 2007
Drug: Levetiracetam; Carbamazepine Controlled Release (CBZ-CR) and 1 more · For: Epilepsy
Sites: Adelaide, Australia; Bedford Park, Australia; Brisbane, Australia · 229 sites in all
- A Study of Aripiprazole (Abilify) in Patients With Bipolar ManiaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00261443 · 1,270 participants · Start Sep 2005 · Primary completion Jun 2009
Drug: Lithium or Valproate with placebo (PBO); Lithium or Valproate with Aripiprazole · For: Bipolar Disorder
Sites: Tuscaloosa, Alabama; Anaheim, California; Cerritos, California · 83 sites in all
- Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or DivalproexPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT01358357 · 965 participants · Start Jun 2011 · Primary completion Apr 2015
Drug: Lurasidone; Placebo · For: Bipolar I Disorder
Sites: Dothan, Alabama; Glendale, California; Los Angeles, California · 105 sites in all
- A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With EpilepsyPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00236717 · 865 participants · Start Sep 1997
Drug: Topiramate; Carbamazepine; Valproate · For: Epilepsy; Seizures
- Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I DisorderPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00081380 · 710 participants · Start Mar 2004
Drug: Seroquel®, quetiapine fumarate (atypical antipsychotic); lithium (mood stabilizer) and 1 more · For: Bipolar Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 94 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3,110
- seizure2,678
- weight increased2,181
- nausea2,123
- off label use2,123
- fatigue1,981
- somnolence1,922
- pain1,905
- tremor1,853
- fall1,788
- anxiety1,723
- vomiting1,654
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,203 |
| 2005 | 1,347 |
| 2006 | 1,267 |
| 2007 | 1,289 |
| 2008 | 1,683 |
| 2009 | 2,925 |
| 2010 | 2,531 |
| 2011 | 2,325 |
| 2012 | 2,288 |
| 2013 | 1,971 |
| 2014 | 2,048 |
| 2015 | 2,701 |
| 2016 | 2,840 |
| 2017 | 2,368 |
| 2018 | 2,214 |
| 2019 | 2,253 |
| 2020 | 2,011 |
| 2021 | 2,122 |
| 2022 | 2,178 |
| 2023 | 1,897 |
| 2024 | 1,867 |
| 2025 | 1,954 |
| 2026 | 1,366 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Depakote ER (Divalproex Sodium)
2024 spending
$9.2M
Beneficiaries
2,044
12,774 claims
Per beneficiary
$4,488
$3.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $19,007,051 |
| 2021 | $17,664,980 |
| 2022 | $16,317,136 |
| 2023 | $11,067,971 |
| 2024 | $9,172,919 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapy of impulse control disorders: A systematic review.
Tahir T, Wong MM, Maaz M, et al. · Psychiatry Res 2022 · Systematic Review
- Comparative efficacy, safety, and tolerability of pharmacotherapies for acute mania in adults: a systematic review and network meta-analysis of randomized controlled trials.
Huang W, He S, Liu M, et al. · Mol Psychiatry 2025 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.
Bahji A, Bach P, Danilewitz M, et al. · Addiction 2022 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis.
Bahji A, Ermacora D, Stephenson C, et al. · J Affect Disord 2020 · Network Meta-Analysis, Systematic Review
- Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials.
Zhang CQ, Li HY, Wan Y, et al. · Front Pharmacol 2022 · Systematic Review
- Episodic migraines in children: limited evidence on preventive pharmacological treatments.
Shamliyan TA, Kane RL, Ramakrishnan R, et al. · J Child Neurol 2013 · Research Support, N.I.H., Extramural, Systematic Review
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.